WAVE Life Sciences Ltd.

WVE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.12 0.07 −2.19%
Market cap
$628.6M
P/E
0.0×
Fwd P/E
−6.2×
Dividend yield
—
F-score
3/9
Altman Z
11.34
Beneish M
−2.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
11.24 67.10 20.21 18.13
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(27.49) (84.88) (24.37) (22.12)
P/B ratio
9.86 5.53 2.84 2.61
EV/Sales
9.44 53.01 12.63 10.63
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(5.21) (12.03) (4.90) (3.60)
Current Ratio
2.51 6.47 11.26 9.99
Net Debt/EBITDA
3.63 11.11 18.78 6.87
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(10.11%) (7.18%) (14.62%) (18.76%)
Free Cash Flow Yield
(16.14%) (6.56%) (12.75%) (16.30%)
Free Cash Flow per Share
(0.27) (0.20) (0.30) (0.27)
Book value per Share
0.74 3.07 2.56 2.22
Free Cash Flow
(44.91) (33.77) (59.99) (54.47)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates